ClinicalTrials.gg
CompletedNCT00740792Updated Sep 7, 2012Results posted

A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

A Phase 3 interventional study of azelastine HCl/fluticasone propionate and azelastine Hcl in Seasonal Allergic Rhinitis, sponsored by Meda Pharmaceuticals. Completed at 39 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-09-07.

Sponsored by Meda Pharmaceuticals (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
776
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing azelastine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. azelastine · Rhinitis, Allergic, Seasonal.

Enrollment
3rd of 16
776 · median 415
Started
2008
with 3 others
Phase 3
9 of 16
none open now
Registered
6th of 16
by date
Lead sponsor
7 of 16
Meda Pharmaceuticals

Among the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal, this one is the 3rd largest by enrollment, is one of 4 that started in 2008, is one of 9 in phase 3, and was the 6th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About azelastine

azelastine: first FDA approval 1996 (ASTELIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

The purpose of this study is to determine if two allergy medications (formulated azelastine and fluticasone product) are more effective than placebo or either medication alone (azelastine or fluticasone)

Read the detailed description

This will be a Phase III, randomized, double-blind, placebo-controlled, parallel-group study in subjects with moderate-to-severe seasonal allergic rhinitis (SAR). The study will begin with a 7-day, single-blind, placebo lead-in period (Day -7 to Day 1). Subjects will be instructed to take placebo lead-in medication twice daily (1 spray per nostril), approximately every 12 hours. On Day 1, subjects who satisfy the symptom severity requirements and continue to meet all of the study inclusion/exclusion criteria will be randomized in a 1:1:1:1 ratio to receive 1 spray per nostril twice daily of MP29-02, azelastine hydrochloride, fluticasone propionate, or placebo nasal spray.

Efficacy will be assessed by the change from baseline in the subject-reported 12-hour reflective Total Nasal Symptom Score (TNSS). On Days 1 through 14, subjects will rate the instantaneous and reflective TNSS symptoms of sneezing, nasal congestion, runny nose, and nasal itching; the instantaneous and reflective total ocular symptom score (TOSS) symptoms of itchy eyes, watery eyes and eye redness; the symptom of postnasal drip will be rated, reflectively, twice daily (AM and PM) in a diary prior to the dose of study medication. Symptoms will be scored on a 0 to 3 scale (0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, 3 = severe symptoms), such that the maximum daily symptom severity score will be 24 for the TNSS and 18 for the TOSS. Additional secondary efficacy variables will include reflective individual nasal and ocular symptom scores, as well as change from Baseline to Day 14 in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

Subjects ≥ 18 years of age will complete the RQLQ on Day 1 (prior to dosing) and Day 14. Subjects will return to the clinic on Day 7 for an interim evaluation. After completing the 2-week double-blind treatment period, subjects will return to the clinic on Day 14 (or at time of early termination) for an end-of-study evaluation. Safety and tolerability assessments will be made on Days 7 and 14. Tolerability will be evaluated by subject-reported adverse events (AEs), nasal examinations, and vital signs assessments.

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects 12 years of age and older
  • Provide written /pediatric assent. If the subject is a minor, parent or legal guardian must give written informed consent
  • Subjects must have moderate-to-severe rhinitis, defined as having one or more of the following:

    1. Sleep disturbance
    2. Impairment of daily activities, leisure and/or sport
    3. Impairment of school or work
    4. Troublesome symptoms
  • Screening Visit: Have a 12-hour reflective TNSS of at least 8 of 12 and a congestion score of 2 or 3 on Visit 1
  • Randomization Visit: Have a 12-hour reflective TNSS (AM or PM) of at least 8 on 3 separate symptom assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1) during the Lead-in Period.
  • Randomization Visit: Have an AM or PM 12-hour reflective nasal congestion score of 2 or 3 must have been recorded on 3 separate symptom assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1) Randomization Visit: Have an instantaneous TNSS score of 8 or more at time point zero, just prior to beginning the onset of action assessment
  • Have taken at least 10 doses of the lead-in medication
  • Willing and able to comply with the study requirementsAt least a 2-year history of SAR during Fall allergy season
  • The presence of IgE-mediated to a local Fall pollen, confirmed by a positive response to skin prick within the last year. A positive response is defined as a wheal diameter of at least 3 mm larger than the negative control.
  • General good health and free of disease or concomitant treatment that could interfere with the interpretation of the study results
  • Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit
  • Subjects currently receiving sublingual immunotherapy are excluded. A 6-month is required following the last dose of sublingual immunotherapy.

Exclusion criteria

Exclusion Criteria:

  • On Focused Nasal Examination, the presence of any superficial and moderate nasal mucosal erosion, nasal mucosal ulceration, or nasal septum perforation at either the screening visit or randomization visit
  • Other nasal disease(s) likely to affect deposition of intranasal medication
  • Nasal surgery or sinus surgery within the previous year.
  • Chronic sinusitis - more than 3 episodes per year
  • Planned travel outside of the pollen area during the study period
  • The use of any drug within 30 days prior to Day -7.
  • Presence of any to drugs similar to azelastine hydrochloride or fluticasone propionate
  • Women who are pregnant or nursing
  • Women of who are not abstinent or not practicing a medically acceptable method of *
  • Respiratory Tract Infections within 14 days prior to Day -7
  • Respiratory Tract Infections requiring antibiotic treatment 14 days prior to Day -7
  • Asthma (with the exception of intermittent asthma).
  • Significant pulmonary disease including
  • arrhythmia or symptomatic cardiac conditions
  • A known history of alcohol or drug abuse within the last 2 years
  • Existence of any surgical or medical condition or physical or laboratory findings that could interfere with study result interpretation.
  • Patients with a history of Glaucoma
  • Clinically relevant abnormal physical findings within 1 week of randomization that may preclude compliance with the study procedures
  • Employees of the research center or private practice and their family members are excluded
  • Subjects who participated in protocol MP4001 or MP4002
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
776 participants (actual)

Study arms

  • Experimental
    azelastine HCl/fluticasone propionate

    nasal spray

    Drug: azelastine HCl/fluticasone propionate

  • Active comparator
    azelastine HCL

    nasal spray

    Drug: azelastine Hcl

  • Active comparator
    fluticasone propionate

    nasal spray

    Drug: fluticasone propionate

  • Placebo comparator
    placebo

    nasal spray

    Drug: placebo

Interventions

  • Drugazelastine HCl/fluticasone propionate

    Drug pages: Azelastine · Fluticasone

    azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID

    Also known as: MP29-02

  • azelastine Hcl 548 mcg one spray per nostril BID

    Also known as: azelastine hydrochloride

  • fluticasone propionate 200 mcg one spray per nostril BID

  • Drugplacebo

    placebo one spray per nostril BID

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)

    change from baseline in 12-hour reflective(how you felt over the previous 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period. The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improvement.

    Time frame: day1 to 14 days

Secondary outcomes

  1. Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)

    change from baseline in 12-hour instantaneous ( how do you feel now) total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period. The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative value is suggestive of improvement.

    Time frame: day 1 to14

  2. Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)

    adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.

    Time frame: day 1 to day 14

07

Results

Posted Sep 7, 2012

Participant flow

Participant flow — Overall Study
MilestoneMP29-02Azelastine HCLFluticasone PropionatePlacebo
Started193194189200
Completed183186180190
Not completed108910
Withdrew: Adverse event3113
Withdrew: Lack of efficacy1103
Withdrew: Lost to follow-up2100
Withdrew: Protocol violation0102
Withdrew: Withdrawal by subject1100
Withdrew: Administrative3382

Outcome measures

PrimaryChange From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)

change from baseline in 12-hour reflective(how you felt over the previous 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period. The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improvement.

Time frame:
day1 to 14 days
Reported as:
Least squares mean · units on a scale
Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)
units on a scaleMP29-02Azelastine HCLFluticasone PropionatePlacebo
Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)-5.5 ± 5.2-4.5 ± 4.6-4.6 ± 5.1-3.0 ± 3.9
SecondaryChange From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)

change from baseline in 12-hour instantaneous ( how do you feel now) total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period. The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative value is suggestive of improvement.

Time frame:
day 1 to14
Reported as:
Least squares mean · units on a scale
Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)
units on a scaleMP29-02Azelastine HCLFluticasone PropionatePlacebo
Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)-5.2 ± 5.3-4.2 ± 4.6-4.3 ± 5.2-2.4 ± 4.2
SecondaryChange From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)

adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.

Time frame:
day 1 to day 14
Reported as:
Least squares mean · units on a scale
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
units on a scaleMP29-02Azelastine HCLFluticasone PropionatePlacebo
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)-1.7 ± 1.3-1.4 ± 1.3-1.5 ± 1.3-1.0 ± 1.3

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MP29-02—1/193 (0.5%)24/193 (12.4%)
Azelastine HCL—0/194 (0%)33/194 (17%)
Fluticasone Propionate—0/189 (0%)15/189 (7.9%)
Placebo—0/200 (0%)13/200 (6.5%)
Most frequent serious events
Most frequent serious events
EventMP29-02Azelastine HCLFluticasone PropionatePlacebo
hepatitis CHepatobiliary disorders1/1930/1940/1890/200
Most frequent other events
Most frequent other events
EventMP29-02Azelastine HCLFluticasone PropionatePlacebo
dysgeusiaGastrointestinal disorders4/19314/1941/1891/200
headacheNervous system disorders6/1934/1945/1892/200
oropharyngeal painRespiratory, thoracic and mediastinal disorders2/1934/1945/1892/200
epistaxisRespiratory, thoracic and mediastinal disorders3/1934/1943/1895/200
mucosal erosionGeneral disorders3/1930/1940/1890/200
coughRespiratory, thoracic and mediastinal disorders2/1931/1940/1890/200
upper respiratory tract infectionInfections and infestations1/1932/1941/1891/200
nasal discomfortRespiratory, thoracic and mediastinal disorders1/1932/1940/1890/200
nasopharyingitisInfections and infestations1/1932/1940/1890/200
nauseaGastrointestinal disorders1/1930/1940/1892/200

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MP29-02Azelastine HCLFluticasone PropionatePlaceboTotal
<=18 years1212141755
Between 18 and 65 years176178172181707
>=65 years543214
Age Continuous
Age Continuous(years)MP29-02Azelastine HCLFluticasone PropionatePlaceboTotal
Mean38.8 ± 14.138.2 ± 13.537.0 ± 13.637.2 ± 13.037.8 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)MP29-02Azelastine HCLFluticasone PropionatePlaceboTotal
Female126128121119494
Male67666881282
Region of Enrollment
Region of Enrollment(participants)MP29-02Azelastine HCLFluticasone PropionatePlaceboTotal
United States193194189200776
08

Study locations

39 sites
  • Allergy, Asthma and Immunology Associates
    Scottsdale, Arizona 85251, United States
  • Clinical Research Center
    Encinitas, California 92024, United States
  • AABI Associates Medical Group
    Fountain Valley, California 92708, United States
  • William Ebbling, MD Inc
    Fresno, California 93720, United States
  • Allergy & Asthma Care Center of So. Cal
    Long Beach, California 90808, United States
  • Allergy Research Foundation
    Los Angeles, California 90025, United States
  • Southern California Research
    Mission Viejo, California 92691, United States
  • Allergy Associates Medical Group Inc
    San Diego, California 92120, United States
  • Bensch Research Associates
    Stockton, California 95207, United States
  • Storms Clinical Research Institute
    Colorado Springs, Colorado 80907, United States
  • Colorado Allergy and Asthma Centers
    Denver, Colorado 80230, United States
  • Clinical Research Atlanta
    Atlanta, Georgia 30342, United States
  • Atlanta Allergy and Asthma Clinic
    Stockbridge, Georgia 30281, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Sneeze, Wheeze and Itch Associates
    Normal, Illinois 61761, United States
  • Kansas City Allergy and Asthma
    Overland Park, Kansas 66210, United States
  • Northeast Medical Research Associates
    North Dartmouth, Massachusetts 02747, United States
  • Clinical Reseacrh Institute
    Minneapolis, Minnesota 55402, United States
  • Clinical Research Institute
    Plymouth, Minnesota 55441, United States
  • The Clinical Research Center
    St. Louis, Missouri 63141, United States
  • The Asthma and Allergy Center
    Papillion, Nebraska 68046, United States
  • Atlantic Research Center
    Ocean, New Jersey 07712, United States
  • Princeton Center for Clinical Research
    Skillman, New Jersey 08558, United States
  • Research Asthma, Sinus and Allergy Centers
    Warren, New Jersey 07059, United States
  • North Carolina Clinical Research
    Raleigh, North Carolina 27607, United States
  • Bernstein Clinical Research Center
    Cincinnati, Ohio 45231, United States
  • Allergy and Consultants of NJ/PA
    Collegeville, Pennsylvania 19426, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • Asthma and Allergy Research Associate
    Upland, Pennsylvania 19013, United States
  • National Allergy, Asthma and Urticaria of Charleston
    Charleston, South Carolina 29407, United States
  • East Tennesse Center for Clinical Research
    Knoxville, Tennessee 37909, United States
  • Allergy and Asthma Associates
    Austin, Texas 78731, United States
  • Allergy and Asthma Center of Austin
    Austin, Texas 78759, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Jane Lee, MD, PA Research Center
    Dallas, Texas 75246, United States
  • Central Texas Health Research
    New Braunfels, Texas 78130, United States
  • Southwest Allergy and Asthma Center, P.A.
    San Antonio, Texas 78229, United States
  • Sylvana Research Associates
    San Antonio, Texas 78229, United States
  • Intermountain Clinical Research
    Draper, Utah 84020, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 3 years 10 months after primary completion. A results delay was requested in Jun 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2008
First posted
Aug 25, 2008
Start
Aug 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results delay requested
Jun 23, 2011
Results first posted
Sep 7, 2012
Last update
Sep 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00740792
Responsible party
Sponsor
First posted
Aug 25, 2008
Start date
Aug 2008
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Sep 7, 2012
Last update
Sep 7, 2012

Study contacts

Lewis M Fredane, MD
study director · Meda Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azelastine · Fluticasone

Start the discussion